FDA clears feline amlodipine as BOAS injectable draws attention: full analysis
A new FDA approval is the clearest clinical takeaway from this week’s veterinary news: on April 29, 2026, the agency approved Amodip, an amlodipine besylate chewable tablet for the control of systemic hypertension in cats. That makes it the first FDA-approved amlodipine product for veterinary use and only the second FDA-approved product indicated for feline hypertension, giving clinicians a labeled option in a category that has long relied heavily on human formulations used off label. (fda.gov)
The approval lands in an area of medicine where the unmet need has been familiar for years. Systemic hypertension in cats is often associated with chronic kidney disease, but it can also occur idiopathically or alongside other chronic disease states, and untreated hypertension can damage the eyes, kidneys, heart, and central nervous system. In routine practice, blood pressure measurement itself can be tricky because stress and “white coat” effects complicate interpretation, which is one reason feline-specific products and clear monitoring guidance matter. (fda.gov)
According to the FDA, Amodip is dosed daily at a standard starting dose for the first 14 days, with dose escalation permitted if the response is inadequate after that period. The agency also notes that cats under 2.5 kg can’t be accurately dosed with the product, and it recommends regular blood pressure monitoring plus early bloodwork checks for kidney and liver values. Ceva Santé Animale is the sponsor. The FDA’s recent approvals listing shows the product was approved under NADA 141-613 on April 29, 2026. (fda.gov)
The week’s other headline clinical-research item is much more preliminary, but still attention-grabbing. Investigators working with Melbourne-based Snoretox and RMIT University published a pilot study in The Veterinary Journal describing Snoretox-1, an injectable therapy intended to improve airway muscle tone in dogs with brachycephalic obstructive airway syndrome. In the six-dog British bulldog pilot, the therapy reportedly reduced BOAS severity by at least one grade for 20 to 53 weeks, and RMIT said all six dogs showed visible improvement and could complete a brisk walk that had previously been difficult. The team has said a larger-scale trial is planned, and it has emphasized that more research and regulatory review are still needed before broader use. (sciencedirect.com)
That BOAS work is drawing interest because it targets a stubborn clinical gap. Surgery and weight management remain the mainstays of treatment, but outcomes vary, and the RMIT release cites research suggesting that up to 60% of affected dogs still have breathing problems after surgery. The researchers also reported improvement in dogs that had responded poorly to previous surgery, raising the possibility that an injectable approach could someday serve as an adjunct or alternative in selected cases. That said, the evidence base is still extremely small, and the company’s own materials frame the program as developmental rather than practice-ready. (rmit.edu.au)
The third item in the weekly roundup points to a longer-horizon shift in veterinary oncology. A February 19, 2026, Science paper, highlighted by Cornell, analyzed 493 feline tumor-normal tissue pairs spanning 13 cancer types and found substantial overlap between feline and human cancer genes. Cornell researchers pointed in particular to parallels between feline mammary tumors and some human breast cancer subtypes, while noting that TP53 mutations appeared in 33% of feline tumors studied, close to the 34% reported in a comparison human dataset. Researchers involved in the project said the findings support treating feline and human cancer as a “shared biological challenge,” not entirely separate problems. (news.cornell.edu)
For veterinary professionals, the practical hierarchy here is important. Amodip is the immediate clinical story because it changes prescribing options now: a labeled feline chewable could improve adherence for pet parents, reduce reliance on manipulated human tablets, and support more standardized hypertension management in general practice and internal medicine. Snoretox-1 is intriguing, but it’s still a signal-generating pilot and not something clinicians can yet fold into standard BOAS protocols. The feline oncogenome study is less about tomorrow morning’s caseload and more about where oncology is headed, especially as comparative genomics begins to shape diagnostics, trial design, and potentially targeted treatment strategies. (fda.gov)
What to watch: In the near term, watch for Amodip’s rollout and any additional prescribing or field-use detail from Ceva and FDA materials; over the medium term, the key question is whether Snoretox-1 can replicate its early results in larger, controlled studies; and in oncology, expect follow-on work that tries to turn the new feline cancer atlas into clinically useful biomarkers and therapeutic targets. (fda.gov)